{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:00:38Z","timestamp":1791489638521,"version":"4.3.4"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":242,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101417","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:57:35Z","timestamp":1788566255000},"page":"101417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A landscape analysis of Japanese tolerability assessments in oncology drug development"],"prefix":"10.1016","volume":"49","author":[{"given":"Hiroe","family":"Kitagaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanami","family":"Nojiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0117-3961","authenticated-orcid":false,"given":"Hideki","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ctarc.2026.101417_bib0001","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1111\/cts.13660","article-title":"Trends in oncology drug lags in Japan from 2001 to 2020: a cross-sectional study","volume":"16","author":"Maeda","year":"2023","journal-title":"Clin. Transl. Sci."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101417_bib0010","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70257","article-title":"New horizon in clinical development strategy in Japan based on new guideline on Japanese phase 1 studies prior to multi-regional clinical trials","volume":"18","author":"Fukuhara","year":"2025","journal-title":"Clin. Transl. Sci."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101417_bib0011","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/cpt.70001","article-title":"Drug loss in Japan: a comparative analysis with Europe for new drugs developed by emerging biopharma companies","volume":"119","author":"Kobayashi","year":"2026","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ctarc.2026.101417_bib0015","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening of the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101417_bib0016","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/cpt.2080","article-title":"Evolving landscape of new drug approval in Japan and lags from international birth dates: retrospective regulatory analysis","volume":"109","author":"Tanaka","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ctarc.2026.101417_bib0017","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s10637-014-0080-y","article-title":"Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and western countries","volume":"32","author":"Maeda","year":"2014","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ctarc.2026.101417_bib0018","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1007\/s10147-015-0825-4","article-title":"Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan?","volume":"20","author":"Maeda","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101417_bib0019","article-title":"Labour and Welfare\/Pharmaceuticals and Medical Devices Agency. The background and content of the notification","author":"Health","year":"2025","journal-title":"Multi-Reg. Clin. Trials Symp."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101417_bib0020","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1248\/bpb.b25-00030","article-title":"Differences in approved doses and drug lag in drugs approved between 2012 and 2021: a comparison between Japan and the U.S","volume":"48","author":"Koyama","year":"2025","journal-title":"Biol. Pharm. Bull."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101417_bib0022","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1002\/cpdd.1044","article-title":"Surveys\/research exploring Japanese phase I studies in global drug development: are they necessary prior to joining global clinical trials?","volume":"10","author":"Hirano","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ctarc.2026.101417_bib0025","first-page":"199","article-title":"Cost and duration of clinical trials in drug development by Japanese pharmaceutical companies","volume":"39","author":"Okada","year":"2025","journal-title":"Pharmaceut. Med."},{"key":"10.1016\/j.ctarc.2026.101417_bib0026","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1740774519839391","article-title":"Globalization of clinical trials: variation in estimated regional costs of pivotal trials, 2015-2016","volume":"16","author":"Qiao","year":"2019","journal-title":"Clin. Trials"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:39:58Z","timestamp":1791488398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":12,"alternative-id":["S2468294226003278"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101417","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A landscape analysis of Japanese tolerability assessments in oncology drug development","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101417","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101417"}}